HROW Samsung Bioepis and Harrow Present Interim Data from a Large Scale Post Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Bio
HROW Samsung Bioepis and Harrow Present Interim Data from a Large Scale Post Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.